logo

Biomarin Pharmaceutical Inc. (BMRN)



Trade BMRN now with
  Date
  Headline
1/22/2020 6:24:11 AM Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $158 Price Target
1/13/2020 8:31:56 AM BioMarin Plans To Begin Clinical Trial With BMN 307 Gene Therapy
12/23/2019 8:37:29 AM BioMarin Submits BLA To FDA For Valoctocogene Roxaparvovec To Treat Hemophilia A
12/23/2019 8:32:25 AM EMA Validates BioMarin's Marketing Authorization Application For Valoctocogene Roxaparvovec To Treat Severe Hemophilia A
12/16/2019 8:20:38 AM BioMarin Reports Positive Final Results From Phase 3 Study Evaluating Vosoritide
11/14/2019 8:30:47 AM BioMarin Updates On Clinical Program For Vosoritide, Analog Of C-type Natriuretic Peptide
10/23/2019 4:08:50 PM BioMarin Q3 EPS $0.30 Vs. Loss $0.07 Year Ago
9/26/2019 8:39:19 AM BioMarin Submits Clinical Trial Application In U.K. For Investigational Gene Therapy For PKU
8/1/2019 4:22:00 PM BioMarin Q2 Loss/share $0.21 Vs. Loss $0.09 Year Ago
7/10/2019 6:50:34 AM Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $128 Price Target
7/9/2019 8:32:29 AM BioMarin Appoints Liz McKee Anderson To Board, Effective July 15
7/8/2019 8:03:57 AM BioMarin Plans To Submit For Authorization Of Valoctocogene Roxaparvovec To Treat Severe Hemophilia A In Q4 In US,EU
  
 
>